eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
A replay of the webcasts will be available for 30 days following the event.
- A replay of the webcasts will be available for 30 days following the event.
- eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.
- eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK).
- eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.